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Abstract
Background:  Gabapentin is a structural analogue of gamma-aminobutyric acid with strong
anticonvulsant and analgesic activities. Important discrepancies are observed on the effectiveness
and potency of gabapentin in acute nociception and sensitization due to inflammation and
neuropathy. There is also some controversy in the literature on whether gabapentin is only active
in central areas of the nervous system or is also effective in the periphery. This is probably due to
the use of different experimental models, routes of administration and types of sensitization. The
aim of the present study was to investigate the influence of the spinal cord sensitization on the
antinociceptive activity of gabapentin in the absence and in the presence of monoarthritis and
neuropathy, using the same experimental protocol of stimulation and the same technique of
evaluation of antinociception.
Methods:  We studied the antinociceptive effects of iv. gabapentin in spinal cord neuronal
responses from adult male Wistar rats using the recording of single motor units technique.
Gabapentin was studied in the absence and in the presence of sensitization due to arthritis and
neuropathy, combining noxious mechanical and repetitive electrical stimulation (wind-up).
Results: The experiments showed that gabapentin was effective in arthritic (max. effect of 41 ±
15% of control and ID50 of 1,145 ± 14 micromol/kg; 200 mg/kg) and neuropathic rats (max. effect
of 20 ± 8% of control and ID50 of 414 ± 27 micromol/kg; 73 mg/kg) but not in normal rats. The
phenomenon of wind-up was dose-dependently reduced by gabapentin in neuropathy but not in
normal and arthritic rats.
Conclusion: We conclude that systemic gabapentin is a potent and effective antinociceptive agent
in sensitization caused by arthritis and neuropathy but not in the absence of sensitization. The
potency of the antinociception was directly related to the intensity of sensitization in the present
experimental conditions. The effect is mainly located in central areas in neuropathy since wind-up
was significantly reduced, however, an action on inflammation-induced sensitized nociceptors is
also likely.
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Background
Gabapentin is a structural analogue of gamma-aminobu-
tyric acid with a strong anticonvulsant activity. It is also an
effective agent in the treatment of neuropathic pain [1,2]
with a mechanism of action, that was initially thought to
involve the modulation of GABA-ergic transmission, but
that it currently seems more related to the blockade of
voltage-gated calcium channels [3-6].
Although gabapentin is an effective analgesic in different
types of neuropathies [7,8], important differences are
observed when comparing the effectiveness and potency
of the drug in studies in humans [9,10] and rodents [11].
Gabapentin also seems to be an effective analgesic drug in
some models of inflammatory pain [12,13] but not in all
tests [14,15] nor in all studies [11,16-18]. The differences
in the results appear to be very dependent on the model
of hyperalgesia utilized, the way the drug is administered
and the tests used [19]. Opposite results have also been
reported when studying the antinociceptive activity of
gabapentin in the absence of sensitization, ranging from a
facilitation of nociceptive neuronal activity [12] to a vir-
tual full inhibition of responses [20].
There is also some controversy in the literature on
whether gabapentin is only active in central areas of the
nervous system or whether it is also effective in the periph-
ery [4,14,20-23]. The discrepancies observed might be
due to the different techniques used to assess the effect of
gabapentin, as well as the different experimental proto-
cols, types of stimulation and models of sensitization.
The aim of the present study was to investigate the influ-
ence of the spinal cord sensitization on the antinocicep-
tive activity of gabapentin in the absence and in the
presence of monoarthritis or neuropathy, using the same
experimental protocol of stimulation and the same tech-
nique of evaluation of antinociception. Spinal cord noci-
ceptive activity was elicited by noxious mechanical
stimulation and by high intensity repetitive electrical
stimulation that triggers the centrally mediated phenom-
enon of wind-up. Additionally, we examined whether the
systemic administration of gabapentin modulates the
wind-up phenomenon in the three experimental condi-
tions, in order to distinguish a peripheral from a central
action [24].
Methods
Animals and induction of sensitization
The antinociceptive activity of gabapentin (Medichem)
was studied on 23 adult male Wistar rats (225–380 g)
divided into three experimental groups: i) normal animals
(n = 6), ii) animals with monoarthritis (n = 8) and iii) ani-
mals with mononeuropathy (n = 9). Monoarthritis was
induced 16 h before the experiment under halothane
anesthesia (5% in oxygen for induction and 2% for main-
tenance) with an injection of 50 µl carrageenan λ (Sigma,
10 mg/ml, in distilled water) in the right knee cavity. The
degree of articular inflammation was assessed by compar-
ing the knee perimeter before the induction of inflamma-
tion and immediately prior to the experiment.
Mononeuropathy was induced under the same anesthetic
regime, seven days before the experiment, using the par-
tial sciatic nerve ligation technique [25]. The development
of hyperalgesia in animals with neuropathy was assessed
by behavioral experiments, studying withdrawal reflex
responses evoked by mechanical and thermal stimulation.
Mechanical stimulation was applied by means of Von Frey
filaments (60, 80, 100, 200, 300 and 500 mN) following
the technique described in detail previously [26,27]. The
rats were placed on a raised wire mesh grid under plastic
chambers. Each filament was applied ten times for
approximately 1 s to the plantar surface of each hind paw
in an ascending series and the total number of positive
responses was counted. A response was considered posi-
tive when a withdrawal of the paw due to the application
of the stimulus was observed. Thermal hyperalgesia was
assessed by measuring paw withdrawal latencies to 55°C
radiant heat generated by an algesimeter (Ugo Basile
plantar test; [28]). Two consecutive thermal stimuli were
applied to each of the paws with an interval of 2–3 min
between tests. In order to avoid tissue damage, a maxi-
mum cutoff time was set to 17 s. Tests were made previous
to the nerve ligation and at 1, 4 and 7 days after the induc-
tion of neuropathy. In all cases, the induction of arthritis
and neuropathy produced a significant increment of noci-
ceptive responses that was considered as hyperalgesia due
to sensitization.
Recording of single motor units
The recording of spinal cord neuronal nociceptive
responses following the single motor unit (SMU) tech-
nique has been described in detail several times [29-33].
Briefly, the preparatory surgery was performed under
halothane anesthesia (5% in oxygen for induction and
2% for maintenance) and only consisted of the cannula-
tion of the trachea, two superficial branches of the jugular
veins and one carotid artery. One of the veins was used for
the continuous administration of α-chloralose, whereas
the drugs studied in the experiments were administered
through the other branch. The cannulation of the carotid
artery was utilized for the monitorization of mean arterial
pressure. Halothane was discontinued after surgery and
the anesthesia was maintained with α-chloralose (50 mg/
kg for induction and 25 mg/kg/h, by perfusion pump, for
maintenance in a rate of 1 ml/h to assure a correct animal
hydration). Core temperature was maintained at 37 ±
0.5°C by means of feedback controlled blanket. Blood
pressure was monitored continuously during the experi-
ments and rats with a systolic pressure below 100 mmHgJournal of Neuroinflammation 2007, 4:15 http://www.jneuroinflammation.com/content/4/1/15
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before the administration of any drug were rejected for the
experiment. In all cases the preparation was left to rest for
at least one hour after the surgery before any drug was
tested.
Nociceptive activity was elicited in 3 min cycles consisting
of 10 s noxious mechanical stimulation and one train of
sixteen percutaneous electrical stimuli (2 ms pulse width,
1 Hz and twice the threshold intensity for the recruitment
of C-fibers) applied to the most sensitive area of the cuta-
neous receptive field of the unit. Figures 1 and 3 show
examples of the protocol followed in all the experiments.
Mechanical stimulation was performed by a computer-
controlled pincher device (Estimec, Cibertec, Spain) using
a force of 200 mN over the threshold and applied on an
area of 14 mm2. The threshold force was considered as the
minimum force required to trigger a sustained nociceptive
reflex over the period of 10 s of stimulation (see Figure 1A
for an original recording of spikes recorded with this stim-
ulation). Electrical stimulation was used to study the phe-
nomenon of wind-up (see [24] for review). Data from
electrical stimulation were analyzed by counting C-fiber
mediated inputs (see Figure 1B for an original recording
of the wind-up response). At the end of the experiments
the animals were killed with an overdose of sodium
pentobarbital (Dolethal, Vetoquinol S.A.). All experi-
ments in this study were undertaken in accordance with
Spanish and European Union legislation regarding the
uses of animals for experimental protocols and all efforts
were made to reduce the number of animals used.
Gabapentin (Medichem) was dissolved in distilled water
0.5 µmol/µl and diluted in saline. The drug was prepared
everyday, immediately before it was administered, and
was injected in cumulative log2 regime in a total and con-
stant volume of 0.3 ml. Preliminary experiments showed
that peak effect of gabapentin was observed within the
first 7 min after intravenous administration. According to
this, the doses studied were administered every 3 cycles of
stimulation (9 min). The effect of the highest cumulative
dose was studied for a minimum of 30 min and no further
depression of the responses was observed during this
time. The initial dose used was 40 µmol/kg (7 mg/kg) and
the highest dose was 1,280 µmol/kg (224 mg/kg; Figure 3
shows the protocol of stimulation, some control
responses and the effect of gabapentin observed in the
three experimental conditions). Data are presented as per-
centage of control, control being the average of the
responses in the three cycles (number of spikes recorded
for each of the stimulus and counted and analyzed sepa-
rately) previous to the administration of the drug (mean
± s.e.m.). Wind-up responses are presented as actual mean
number of spikes or as percentage of control in order to
facilitate comparisons. In addition, wind-up-index (total
Induction of sensitization Figure 2
Induction of sensitization. (A) The administration of 50 µl 
of carrageenan in the knee joint induced an evident inflamma-
tion. The circumference of the knee increased significantly 16 
h after the injection of carrageenan. Neuropathy was induced 
seven days before the experiment following the partial sciatic 
nerve ligation technique. (B) Mechanical hyperalgesia was 
studied by applying a series of von Frey filaments previous to 
and at days 1, 4 (not shown) and 7 after the nerve ligation. 
(C) Thermal hyperalgesia was assessed by measuring paw 
withdrawal latencies to 55°C radiant heat using a similar tim-
ing. An intense mechanical and thermal hyperalgesia was 
observed in all tests made after the induction of neuropathy 
(**P < 0.01, ***P < 0.001, comparison vs. control response 
with the two tail unpaired t-test).
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Original single motor unit spikes Figure 1
Original single motor unit spikes. The figure shows 
actual spikes (lower panel) recorded during 10 s of noxious 
mechanical stimulation (A) and a train of 16 electrical stimuli 
(B; wind-up). Top panel shows the number of spikes/s (sp/s) 
recorded for each stimulus as bar histograms (mechanical 
stimulation in mN and electrical pulses as TTL pulses).
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number of spikes/spikes recorded in the first pulse ×
number of pulses; see [24] for more details and references
within) has been considered for the control comparison.
The effects of the drug in single motor unit experiments,
the comparisons of the effects between experimental con-
ditions and the comparison of regression curves were
assessed with the one-way analysis of variance (ANOVA)
with post-hoc Tukey's multiple comparison test, whereas
the comparison of ID50s, level of inflammation and
results in behavioral experiments were made with the two
tail unpaired t-test using commercial software (GraphPad
Prism and GraphPad InStat).
Results
The administration of carrageenan in the knee cavity (Fig-
ure 2) induced a significant increase of the knee circumfer-
ence (increment of 18 ± 2%; from 63 ± 0.8 to 74 ± 1.4
mm; P < 0.01). In animals with mononeuropathy the
number of nociceptive responses to mechanical stimula-
tion increased from a mean of 18 ± 2 to 47 ± 2 responses
per animal (P < 0.001; Figure 2). In addition, the latency
to noxious thermal stimulation decreased from 10 ± 0.6
to 6.5 ± 0.4 s (P < 0.01; Figure 2).
In electrophysiological experiments, the mean forces used
for mechanical stimulation in the three experimental
groups were 0.8 ± 0.1 N in normal animals (mean thresh-
old of 0.65 ± 0.2 N), 0.8 ± 0.1 N in arthritic animals
(mean threshold of 0.7 ± 0.1 N), and 0.9 ± 0.1 N in ani-
mals with neuropathy (mean threshold of 0.76 ± 0.1 N).
The mean intensities of electrical stimulation were 2.3 ±
0.7 mA in normal animals (mean threshold of 1.8 ± 0.2
mA), 3.5 ± 0.7 mA in arthritic animals (mean threshold of
2.4 ± 0.6 mA) and 3.4 ± 0.8 mA in animals with neuropa-
thy (mean threshold of 2.1 ± 0.5 mA). Mean control
number of responses elicited by noxious mechanical stim-
ulation was also very similar in the three groups: 372 ± 47
spikes in normal animals, 298 ± 24 spikes in arthritis and
315 ± 19 spikes in neuropathy. The increment of
responses by repetitive electrical stimulation (wind-up
index) in the control responses were similar in the three
experimental groups: 6.2 ± 1.3 in normal rats, 6 ± 0.9 in
monoarthritis and 6.3 ± 1.6 in neuropathy. No significant
differences were observed between the threshold intensi-
ties or mean control number of responses when the three
experimental groups were compared.
The administration of iv. cumulative doses of gabapentin
reduced dose-dependently the SMU responses to noxious
mechanical stimulation in arthritic and neuropathic ani-
mals, but not in normal animals (Figures 3 and 4). In nor-
mal animals, a small reduction of responses (78 ± 2% of
control response, P < 0.05) was only observed with the
highest dose studied (1,280 µmol/kg). In arthritis, the
highest dose studied induced a depression of responses of
41 ± 15% of control (Figure 4; P < 0.01) with a calculated
ID50 of 1,145 ± 14 µmol/kg (200 mg/kg). However, the
most potent antinociception was observed in the group of
neuropathic animals, in which the calculated ID50 was
414 ± 27 µmol/kg (73 mg/kg; P < 0.001 compared to that
in arthritic animals), the maximal effect observed was of
20 ± 8% of control response (Figure 4, P < 0.01) and the
minimum effective dose was 320 µmol/kg (P < 0.01).
Comparison of raw data showed that the effect observed
in neuropathic animals was significantly more intense
than that in arthritic animals for doses of 320 to 1,280
µmol/kg (P < 0.05 in all cases) and in normal animals for
the same doses (320 µmol/kg: P < 0.001; 640 µmol/kg: P
< 0.01 and 1,280 µmol/kg: P < 0.05). In addition, the
effect observed in animals with monoarthritis was signifi-
cantly more intense than that seen in normal animals for
doses of 320 to 1,280 µmol/kg (P < 0.05 in all cases). Sta-
tistical comparison of the regression curves showed a sig-
nificant difference between normal and arthritic animals
(P < 0.01) and between arthritic and neuropathic rats (P <
0.01). As in arthritic rats, the effect of gabapentin was still
significant 30 min after administration (data not shown).
All the units studied showed a progressive increment of
the number of spikes with repetitive electrical stimulation
(wind-up; Figure 1). The phenomenon of wind-up was
not significantly reduced by gabapentin in normal and
Original recordings Figure 3
Original recordings. Original recordings of three different 
single motor units previous to and after the administration of 
iv. cumulative doses of gabapentin in normal (A), arthritic (B) 
and neuropathic animals (C). The units were activated in 
three minute cycles by 10 s of noxious mechanical stimula-
tion and 16 electrical pulses (2 ms pulse width, 1 Hz and 
twice the threshold intensity for the recruitment of C-fibers). 
Gabapentin was administered iv. in log2 cumulative doses 
every three cycles of stimulation (9 minutes) from 40 to 
1,280 µmol/kg (7 to 224 mg/kg). The administration of gabap-
entin dose-dependently reduced the nociceptive responses in 
arthritic and neuropathic animals but not in normal rats.
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arthritic animals (Figures 3 and 5). However, an impor-
tant, dose-dependent and significant reduction of wind-
up was observed after the administration of gabapentin in
animals with neuropathy (Figure 5). In this case, the
reduction of wind-up was significant from the dose of 320
µmol/kg (P < 0.05) and the maximal reduction was of 55
± 20% of control (P < 0.01, Figure 5). The effect of gabap-
entin on wind-up in neuropathic rats was significantly
higher than that in normal animals (P < 0.01) and in
arthritic animals (P < 0.01; statistical comparison of the
regression curves using the one-way analysis of variance
with post-hoc Tukey's multiple comparison test). The
depression of wind-up was still significant 30 min after
the injection of gabapentin (data not shown).
Finally, the intravenous administration of gabapentin was
not followed by any significant change in mean arterial
blood pressure. The mean arterial blood pressure before
the administration of the drugs was 125 ± 12 mmHg in
normal animals, 113 ± 6 mmHg in arthritic animals and
139 ± 7 mmHg in neuropathic animals. After the admin-
istration of the highest dose of gabapentin the values were
110 ± 12, 88 ± 4 and 114 ± 3 mmHg respectively.
Discussion
The main observation made in the present study is the
relationship between the antinociceptive effect of gabap-
entin and the presence and type of spinal cord sensitiza-
tion. The systemic administration of gabapentin was
followed by a slight depression of nociceptive responses
evoked by noxious mechanical stimulation in normal
non-sensitized animals. The reduction of the responses
was significantly more intense in animals with carra-
geenan-induced sensitization and a virtual full inhibition
of responses (less than 25% of control response) was
observed in animals with sensitization due to neuropathy.
Therefore, our results indicate that in similar experimental
conditions, gabapentin is not effective in the reduction of
nociceptive responses evoked in normal animals but it is
very effective in a situation of spinal cord sensitization. In
addition, the antinociceptive effect of gabapentin is more
pronounced when hyperalgesia is induced by neuropathy
than by articular inflammation. The intensity of behavio-
ral responses in animals with neuropathy, as well as the
level of arthritis observed after the administration of car-
rageenan and, in consequence, the intensity of inflamma-
tion-induced sensitization, were similar to those observed
in similar experiments performed previously in our lab
[34-37]. In addition, thresholds for mechanical and elec-
trical stimulation as well as the control number of
Effect of gabapentin on wind-up Figure 5
Effect of gabapentin on wind-up. The administration of 
gabapentin dose-dependently reduced the wind-up phenom-
enon in neuropathic rats with maximal reduction of 55 ± 20% 
of control (P < 0.01). Gabapentin was not efficacious in the 
reduction of wind-up in normal and arthritic animals. The fig-
ure shows the effect of gabapentin on wind-up as percentage 
of control (all groups) and as actual number of C-fiber medi-
ated responses (inset, data for neuropathic rats; only some 
doses are shown for clarity. *P < 0.05, *P < 0.01, comparison 
vs. control response with the one-way ANOVA, with the 
post-hoc Tukey test).
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Antinociceptive effect of gabapentin in responses to noxious  mechanical stimulation Figure 4
Antinociceptive effect of gabapentin in responses to 
noxious mechanical stimulation. The iv. administration 
of gabapentin induced a dose-dependent inhibition of 
responses to noxious mechanical stimulation in arthritic and 
neuropathic rats, but not in normal rats. The calculated 
ID50s were of 1,145 ± 14 µmol/kg (200 mg/kg) in arthritis 
and 414 ± 27 µmol/kg (73 mg/kg) in neuropathy (P < 0.001, 
two tail unpaired t-test). The effect was still significant 30 min 
after the administration of gabapentin. Statistical comparison 
of the regression curves showed a significant difference 
between normal and arthritic animals (P < 0.01; ##) and 
between arthritic and neuropathic rats (P < 0.01; $$).*P < 
0.05, *P < 0.01, comparison vs. control response with the 
one-way ANOVA, with the post-hoc Tukey test.
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responses were similar between groups and similar to
those observed in previous studies performed in our lab-
oratory [27,30,36].
It is necessary to consider that the different antinocicep-
tive activity might be due to a different level of anesthesia,
a depression of the cardiovascular system or even to a dif-
ferent intensity of stimulation. However, the administra-
tion of systemic α-chloralose by perfusion pump ensured
a very stable and similar level of anesthesia in the three
experimental conditions and so it is not likely that the dif-
ferent intensity of analgesia observed in our experiments
was due to a different intensity of anesthesia. In addition,
the intravenous administration of gabapentin did not
modify significantly blood pressure and, on the other
hand, the intensity of stimulation, as well as the number
of spikes recorded in the control cycles of stimulation,
were very similar in all the experiments (see below and
[29,38] for further discussion on these subjects). It seems
more likely that the different antinociceptive activity
observed by the systemic administration of gabapentin
was influenced by the different state of sensitization.
The antinociceptive effects observed after the administra-
tion of gabapentin, on the other hand, might have been
influenced by the experimental technique. The experi-
ments were performed using the recording of nociceptive
withdrawal reflexes as single motor units. This technique
has been used frequently by us and other groups in similar
experiments, since it allows the recording of direct spinal
cord neuronal responses with a minimum of preparatory
surgery. The experiments are performed in a less traumatic
preparation than that needed in other techniques which,
for example, require laminectomy and full exposition of
the spinal cord, avoiding artificial and extra nociceptive
inputs. The experiments are, in this case, carried out in a
much more similar conditions and data are very reproduc-
ible [27,29,38-40].
The recording of SMUs allowed us to test for antinocicep-
tive actions of gabapentin, as well as of many other drugs
[27,36,37] in different states of sensitization. In addition,
the technique allows different protocols of stimulation,
combining natural and electrical stimulation. This is
important in order to have some evidence as to whether
the effect of the drug was located in the periphery, i.e. sen-
sitized nociceptors, or in central areas of the nociceptive
system, especially the spinal cord. Noxious mechanical
stimulation is transduced by nociceptors, and thus anti-
nociceptive agents acting either in the periphery or within
the central nervous system will reduce nociceptive
responses. However, drugs acting mainly on nociceptors
will have no effect on responses to electrical stimulation.
This is because electrical stimulation is not a natural type
of stimulus and, therefore, bypasses nociceptors and
directly activates afferent axons. In addition, electrical
stimulation applied according to the protocol followed in
the present conditions, induces the phenomenon of
wind-up. In this phenomenon, repetitive electrical stimu-
lation induces a progressive increase of nociceptive
responses from spinal cord neurons [24], and is mediated
by NMDA [41,42] and NK1 receptors [43]. A reduction of
wind-up implies an inhibitory action of the circuitry
involved in its generation, which is located in the central
nervous system, at spinal cord level [24], although a mod-
ulation of the system by higher levels in the CNS is also
possible [35]. The important depression of wind-up
observed in animals with neuropathy by gabapentin indi-
cates a central action of the drug rather than a peripheral
effect. This is supported by previous studies in which an
effective action of gabapentin was observed in in vitro cor-
tical [4] and dorsal root ganglion neurons [5]. Although
the effect was variable and dependent on culture condi-
tions and on the expression of calcium channels [6,22].
However, the fact that the depression of responses to nox-
ious mechanical stimulation in animals with arthritis was
not associated to a depression of wind-up indicates that
an action of gabapentin on the periphery cannot be
rejected. In fact, a peripheral action of gabapentin has
been described after intradermal administration of the
drug [23], though controversial results are reported in the
literature (see [23] and references within for further dis-
cussion). Since our experiments, which were made on dif-
ferent states of sensitization but under the same
experimental conditions, showed a different action of
gabapentin on wind-up, it seems logical to argue that a
central effect depends on the type or degree of spinal cord
sensitization. This probably means that the effect of
gabapentin at peripheral and/or central areas depends on
the changes induced in the spinal cord processing of noci-
ceptive system by the sensitization. For example, the
expression of calcium channels, as reported by Martin et
al 2002 [22] and others [44,45]. Nevertheless, the effect
on wind-up is only indicative of a central action and fur-
ther experiments are needed to reject an action at periph-
eral sites in the in vivo situation.
Conclusion
In conclusion, our results show that gabapentin is a
potent and effective antinociceptive agent in situations of
sensitization caused by arthritis and neuropathy but not
in the absence of sensitization. The potency of the antino-
ciception was directly related to the type of sensitization
in the present experimental conditions. The effect is
mainly located at central sites in neuropathy, however an
action on inflammation-induced sensitized nociceptors is
also likely.Journal of Neuroinflammation 2007, 4:15 http://www.jneuroinflammation.com/content/4/1/15
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